Genentech Company Profile

✉ Email this page to a colleague

GENENTECH has nine approved drugs.

There are fifty-six US patents protecting GENENTECH drugs.

There are eight hundred and forty-four patent family members on GENENTECH drugs in fifty-three countries and eighty-six supplementary protection certificates in nineteen countries.

International Patents:	844
US Patents:	56
Tradenames:	6
Ingredients:	6
NDAs:	9
Patent Litigation for Genentech:	See patent lawsuits for Genentech
PTAB Cases with Genentech as patent owner:	See PTAB cases with Genentech as patent owner

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Genentech Inc	ESBRIET	pirfenidone	TABLET;ORAL	208780-001	Jan 11, 2017	AB	RX	Yes	No	8,318,780	⤷ Try a Trial				⤷ Try a Trial
Genentech Inc	XOFLUZA	baloxavir marboxil	TABLET;ORAL	210854-002	Oct 24, 2018		RX	Yes	No	10,759,814	⤷ Try a Trial	Y	Y		⤷ Try a Trial
Genentech Inc	XOFLUZA	baloxavir marboxil	TABLET;ORAL	210854-003	Mar 18, 2021		RX	Yes	Yes	10,633,397	⤷ Try a Trial				⤷ Try a Trial
Genentech Inc	XOFLUZA	baloxavir marboxil	TABLET;ORAL	210854-001	Oct 24, 2018		DISCN	Yes	No	8,927,710	⤷ Try a Trial	Y			⤷ Try a Trial
Genentech Inc	ESBRIET	pirfenidone	TABLET;ORAL	208780-001	Jan 11, 2017	AB	RX	Yes	No	8,609,701	⤷ Try a Trial				⤷ Try a Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Genentech Inc	ESBRIET	pirfenidone	TABLET;ORAL	208780-001	Jan 11, 2017	9,561,217	⤷ Try a Trial
Genentech Inc	ESBRIET	pirfenidone	TABLET;ORAL	208780-002	Jan 11, 2017	9,561,217	⤷ Try a Trial
Genentech Inc	ESBRIET	pirfenidone	TABLET;ORAL	208780-003	Jan 11, 2017	9,561,217	⤷ Try a Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Drugname	Dosage	Strength	Tradename	Submissiondate
➤ Subscribe	Tablets	267 mg, 534 mg and 801 mg	➤ Subscribe	2018-10-15

Subscribe to access the full database, or Try a Trial
Country	Patent Number	Estimated Expiration
France	21C1039	⤷ Try a Trial
World Intellectual Property Organization (WIPO)	2016175224	⤷ Try a Trial
Japan	2021138716	⤷ Try a Trial
Japan	2012509362	⤷ Try a Trial
China	102482219	⤷ Try a Trial
>Country	>Patent Number	>Estimated Expiration

Subscribe to access the full database, or Try a Trial
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1789390	C 2013 038	Romania	⤷ Try a Trial	PRODUCT NAME: VISMODEGIB SI SARURILE SI SOLVATIIACESTUIA; NATIONAL AUTHORISATION NUMBER: EU/1/13/848; DATE OF NATIONAL AUTHORISATION: 20130712; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): CH 62497 01; DATE OF FIRST AUTHORISATION IN EEA: 20130530
1789390	514	Finland	⤷ Try a Trial
1789390	14C0002	France	⤷ Try a Trial	PRODUCT NAME: VISMODEGIB AINSI QUE SES SELS ET SOLVATES; NAT. REGISTRATION NO/DATE: EU/1/13/848 20130712; FIRST REGISTRATION: IKS 62497 20130530
3428170	LUC00198	Luxembourg	⤷ Try a Trial	PRODUCT NAME: BALOXAVIR MARBOXIL OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; AUTHORISATION NUMBER AND DATE: EU/1/20/1500 20210108
3143025	132021000000149	Italy	⤷ Try a Trial	PRODUCT NAME: RISDIPLAM O UN SUO SALE FARMACEUTICAMENTE ACCETTABILE(EVRYSDI); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/21/1531, 20210329
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.